This trial is active, not recruiting.

Conditions solid tumors, thyroid cancer, soft-tissue sarcoma, cholangiocarcinoma
Treatments pazopanib, gsk1120212
Phase phase 1
Sponsor Sidney Kimmel Comprehensive Cancer Center
Collaborator National Comprehensive Cancer Network
Start date October 2011
End date April 2016
Trial size 111 participants
Trial identifier NCT01438554, J1162, NA_00048646


The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety study
Intervention model single group assignment
Masking open label
Treatment will be administered on an outpatient basis. Both drugs are taken orally. Each cycle lasts 28 days. The doses of each drug will depend on when patient enters study.
pazopanib Votrient
gsk1120212 Trametinib

Primary Outcomes

Maximum tolerated dose (MTD) of pazopanib and GSK1120212 when combined in patients with solid tumors
time frame: Approximately one year
Adverse events as a measure of the safety and tolerability profile of pazopanib in combination with GSK1120212 in patients with solid tumors
time frame: Approximately two years

Secondary Outcomes

Objective response rate at six months in patients with advanced thyroid cancer, soft tissue sarcoma and cholangiocarcinoma being treated at the MTD
time frame: Approximately one year
Progression-free survival (PFS) in patients with advanced thyroid cancer, soft tissue sarcoma and cholangiocarcinoma being treated at MTD.
time frame: Approximately one year
Correlation of PK data with radiographic response, PD markers, and the impact of tumor histologic subtype and tumor genotype on radiographic response for patients with advanced thyroid cancer
time frame: Approximately one year
PD marker analysis on peripheral blood mononuclear cells for patients with soft tissue sarcoma and cholangiocarcinoma
time frame: Approximately one year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Dose escalation cohort for all solid tumors is closed to enrollment. - Expansion cohorts: Soft-tissue sarcoma, cholangiocarcinoma, and differentiated thyroid cancer (DTC) cohorts are closed to enrollment. Patients in the DTC cohort must have disease that is able to be biopsied. - Must have measurable disease. - Tumor progression in the 6-month period prior to study drug initiation. - DTC patients: must have radioiodine non-avid lesions, OR radioiodine avid lesions that have not responded to treatment with radioactive iodine. - ECOG performance status less than or equal to 1. - Life expectancy >3 months. - Blood pressure <140 mmHg and <90 mmHg. - LVEF is >= 50% - Must be able to swallow pills. Exclusion Criteria: - Chemotherapy, radiotherapy, other investigational therapy, or major surgery within 4 weeks. - Sarcoma and cholangiocarcinoma ONLY: Prior VEGF-targeted TKI therapy. - Pregnant or currently breastfeeding. - Unresolved toxicity greater than grade 1. - Evidence of active hepatitis or HIV. - Significant cardiovascular disease. - Taking medications known to be strong inducers or inhibitors of CYP3A enzymes. - Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding. - History of gastrointestinal condition causing malabsorption or obstruction. - Cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep vein thrombosis (DVT) within past 6 months. - Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase risk of pulmonary hemorrhage. - Hemoptysis within 6 months of starting treatment. - History of retinal vein occlusion (RVO) or central serous retinopathy (CSR), or predisposing factors to RVO or CSR as assessed by ophthalmic exam. - Known brain mets that are not stable for at least 8 weeks prior to treatment, or patient is on glucocorticoids for brain mets.

Additional Information

Official title Phase I Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma
Principal investigator Nilo Azad, MD
Trial information was received from ClinicalTrials.gov and was last updated in April 2016.
Information provided to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center.